Syndax Pharmaceuticals Inc (SNDX)
- Sector
- Biotechnology
- Last price
- $9.20
- As of
Kresmion compiles this page from SNDX's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Syndax Pharmaceuticals Inc (SNDX): 1 institutional manager tracked by Kresmion reported non-option positions in their 2026Q3 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-11-02.
See the full SNDX dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for SNDX on one page. Preview it with sample data, then open it live with a free account.
Preview the SNDX dossierActive events for SNDX
- mediumEarnings below estimates
Q3-2026: Missed consensus by 9.6%, EPS $-0.55 vs $-0.502 estimate
- high13F: large reduction
CITADEL ADVISORS LLC cut 66% of SNDX (2026Q2)
- high13F: large increase
CITADEL ADVISORS LLC added +448% to SNDX (2026Q2)
- high13F: large increase
MILLENNIUM MANAGEMENT LLC added +929% to SNDX (2026Q2)
- mediumEarnings below estimates
Q2-2026: Missed consensus by 22.4%, EPS $-0.55 vs $-0.4493 estimate
FREE, NO ACCOUNT
Every event on SNDX, as it fires
You are seeing 5 of 10 events recorded on SNDX since 2026-06-05.
The five above landed across 3 days. The other 5 were recorded on 2 other days. 5 of the 10 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
SNDX positions held by the managers we follow (2026Q3)
What the managers we follow bought and sold in Q2 2026
| Manager / security | Market value | % of reported value |
|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC FundCUSIP 87164F105 · 2026Q3 | $3.6M | 0.00% |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. The share of reported value is each position's value over the sum of the values that manager reported for the quarter; option lines are not in that sum, as on each fund page. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, SNDX
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
More data on SNDX
SNDX against its peers
SNDX's operating margin of -158.4% ranks in the 21st percentile of 11 Biotechnology sub-industry peers, fiscal period ending 2025-12-31.
| Metric | SNDX | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 172M USD | 107M USD | 63 | 11 |
| Operating margin | -158.4% | -10.1% | 21 | 11 |
| Net margin | -165.6% | -15.1% | 21 | 11 |
| Return on equity | -441.6% | -33.7% | 3 | 15 |
| 1 year | -44.9% | 11.6% | 9 | 15 |
Peers (17): RIGL, IRWD, GLUE, MGTX, ARDX, ORIC, LXRX, PRME, CRVS, SLDB, TBPH, PHAR, AURA, JANX, SGMT, XOMA.D, NVCT. Left out: LTGO (no annual filing), CTY (no annual filing), BBTX (no annual filing), OBX (no annual filing), IVA (period gap), AKTS (no annual filing), ODTX (no annual filing), ATTO (no annual filing). Fiscal period ending 2025-12-31. Every figure is one full fiscal year read from one annual filing (SNDX: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Cite this data
Kresmion counts the managers it follows that reported a non-option position in SNDX on Form 13F-HR for the latest reporting quarter, orders those positions by the value each filing reports, and lists the company's latest SEC filings and the events Kresmion recorded on SNDX in the last 180 days.
Upstream: SEC EDGAR filings for SNDX
Kresmion, "Syndax Pharmaceuticals Inc (SNDX) institutional holdings and SEC filings", data as of 2026-11-16, https://kresmion.com/research/SNDX. Upstream data: SEC EDGAR filings for SNDX.
Link to this data (HTML):
<a href="https://kresmion.com/research/SNDX">Syndax Pharmaceuticals Inc (SNDX) institutional holdings and SEC filings (Kresmion)</a>
Writing about this? Press contact and ready-to-quote figures
Follow SNDX on a live board
Kresmion is a source-first market terminal for cross-asset market intelligence. Open a board scoped to SNDX for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.